1. Home
  2. LPTH vs TOVX Comparison

LPTH vs TOVX Comparison

Compare LPTH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTH
  • TOVX
  • Stock Information
  • Founded
  • LPTH 1985
  • TOVX 2001
  • Country
  • LPTH United States
  • TOVX United States
  • Employees
  • LPTH N/A
  • TOVX 22
  • Industry
  • LPTH Semiconductors
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPTH Technology
  • TOVX Health Care
  • Exchange
  • LPTH Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • LPTH N/A
  • TOVX 3.2M
  • IPO Year
  • LPTH 1996
  • TOVX 2006
  • Fundamental
  • Price
  • LPTH $2.69
  • TOVX $1.14
  • Analyst Decision
  • LPTH Strong Buy
  • TOVX Strong Buy
  • Analyst Count
  • LPTH 2
  • TOVX 1
  • Target Price
  • LPTH $3.00
  • TOVX $6.00
  • AVG Volume (30 Days)
  • LPTH 364.5K
  • TOVX 97.3K
  • Earning Date
  • LPTH 02-06-2025
  • TOVX 11-12-2024
  • Dividend Yield
  • LPTH N/A
  • TOVX N/A
  • EPS Growth
  • LPTH N/A
  • TOVX N/A
  • EPS
  • LPTH N/A
  • TOVX N/A
  • Revenue
  • LPTH $32,049,325.00
  • TOVX N/A
  • Revenue This Year
  • LPTH $12.63
  • TOVX N/A
  • Revenue Next Year
  • LPTH $16.80
  • TOVX N/A
  • P/E Ratio
  • LPTH N/A
  • TOVX N/A
  • Revenue Growth
  • LPTH N/A
  • TOVX N/A
  • 52 Week Low
  • LPTH $1.04
  • TOVX $1.14
  • 52 Week High
  • LPTH $2.86
  • TOVX $17.00
  • Technical
  • Relative Strength Index (RSI)
  • LPTH 84.03
  • TOVX 36.15
  • Support Level
  • LPTH $2.36
  • TOVX $1.23
  • Resistance Level
  • LPTH $2.86
  • TOVX $1.21
  • Average True Range (ATR)
  • LPTH 0.23
  • TOVX 0.07
  • MACD
  • LPTH 0.09
  • TOVX 0.01
  • Stochastic Oscillator
  • LPTH 84.68
  • TOVX 0.00

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: